Pfizer Inc.'s give-back of rights to Remoxy, the long-acting, tamper-resistant form of oxycodone developed by Pain Therapeutics Inc., put the Austin, Texas-based company in a world of hurt last October, despite its insistence that the pharma partner's decision was based on an internal pipeline prioritization rather than a problem with the drug.